Share on StockTwits
 

Genomic Health (NASDAQ:GHDX) was downgraded by stock analysts at Credit Suisse from an “outperform” rating to a “neutral” rating in a report issued on Friday, TheFlyOnTheWall.com reports.

Genomic Health (NASDAQ:GHDX) opened at 26.52 on Friday. Genomic Health has a 1-year low of $25.50 and a 1-year high of $38.99. The stock has a 50-day moving average of $29.95 and a 200-day moving average of $31.91. The company’s market cap is $815.2 million.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, February 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $69.20 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.35 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on GHDX. Analysts at Bank of America Corp. downgraded shares of Genomic Health to an “underperform” rating in a research note to investors on Wednesday. They now have a $28.00 price target on the stock, down previously from $30.00. Separately, analysts at JMP Securities cut their price target on shares of Genomic Health from $38.00 to $34.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Genomic Health from $33.00 to $28.00 in a research note to investors on Wednesday. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $31.80.

Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.